Gerard P. Zambetti, PhD

    Gerard P. Zambetti, PhD

    Member, St. Jude Faculty
    Vice President and Director of Academic Programs in Biomedical Sciences
    Associate Director for Training and Education, Cancer Center

    Departments

    Pathology

    Contact Information

    Gerard Zambetti, PhD
    Pathology
    MS 276 Room D5006B
    St. Jude Children's Research Hospital
    262 Danny Thomas Place
    Memphis, TN 38105-3678
    Email: gerard.zambetti@stjude.org
    Phone: (901) 595-6028
    FAX: (901) 595-5376

    Education

    MS - Emory University, Atlanta, Georgia
    PhD - University of Florida, Gainesville


    Research Interests

    Function of p53 in tumor suppression and tumorigenesis


    Selected Publications

    Wasserman JD, Zambetti GP, Malkin D. Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Mol Cell Endocrinol 351(1):101-10, 2012.

    Ribeiro RC, Pinto EM, Zambetti GP, Rodriguez-Galindo C. The International Pediatric Adrenocortical Tumor Registry initiative: contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. Mol Cell Endocrinol October 23, 2011.

    Kuribayashi K, Finnberg N, Jeffers JR, Zambetti GP, El-Deiry WS. The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle 10(14):2380-9, 2011.

    Zambetti GP. Diving into in vivo p53 tumor suppressor studies using a new platform mouse model. Cell Cycle 10(16), 2011.

    Pinto EM, Ribeiro RC, Figueiredo BC, Zambetti GP. TP53-associated pediatric malignancies. Genes Cancer 2(4):485-90, 2011.

    Stadanlick JE, Zhang Z, Lee SY, Hemann M, Biery M, Carleton MO, Zambetti GP, Anderson SJ, Oravecz T, Wiest DL. Developmental arrest of T cells in Rpl22-deficient mice is dependent upon multiple p53 effectors. J Immunol 127(2):664-75, 2011.

    Mandl A, Pham LH, Toth K, Zambetti G, Erhardt P. Puma deletion delays cardiac dysfunction in murine heart failure models through attenuation of apoptosis. Circulation 124(1):31-104, 2011.

    Link DC, Schuettpelz LG, Shen D, Wang J, Walter MJ, Kulkarni S, Payton JE, Ivanovich J, Goodfellow PJ, Le Beau M, Koboldt DC, Dooling DJ, Fulton RS, Bender RHF, Fulton LL, Delehaunty KD, Fronick CC, Appelbaum EL, Schmidt H, Abbott R, O'Laughlin M, Chen K, McLellan MD, Varghese N, Nagarajan R, Heath S, Graubert TA, Ding L, Ley TJ, Zambetti GP, Wilson RK,Mardis ER. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 305(15):1568-1576, 2011.

    Boechat GAP, Stinghen ST, Custodio G, Pianovski MAD, Figueiredo FRdO, Jenkins J, Zambetti GP, Ribeiro RC, Figueiredo BC. Placental alkaline phosphatase in pediatric adrenocortical cancer. J Pediatr Hematol Oncol 33(4):149-53, 2011.

    El Wakil A, Doghman M, De Late PL, Zambetti GP, Figueiredo BC, Lalli E. Genetics and genomics of childhood adrenocortical tumors. Mol Cell Endocrinol 336(1-2):169-173, 2011.

    Coloff JL, Mason EF, Altman BJ, Gerriets VA, Liu T, Nichols AN, Zhao Y, Wofford JA, Jacobs SR, Ilkayeva O, Garrison SP, Zambetti GP, Rathmell JC. Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells. J Biol Chem 286(7):5921-33, 2011.

    Bernstein AI, Garrison SP, Zambetti GP, O'Malley KL. 6-OHDA generated ROS induces DNA damage and p53-and PUMA-dependent cell death. Mol Neurodegener 6(2):1-13 2011.

    Kasper LH, Thomas MC, Zambetti GP, Brindle PK. Double null cells reveal that CBP and p300 are dispensable for p53 targets p21 and Mdm2 but variably required for target genes of other signaling pathways. Cell Cycle 10(2), 2011.

    Garrison SP, Thornton JA, Hacker H, Webby R, Rehg JE, Parganas E, Zambetti GP, Tuomanen EI. The p53-target gene puma drives neutrophil-mediated protection against lethal bacterial sepsis. PLoS Pathog 6(12):e1001240, 2010.

    Pinto EM, Ribeiro RC, Kletter GB, Lawrence JP, Jenkins JJ, Wang J, Shurtleff S, McGregor L, Kriwacki RW, Zambetti GP. Inherited germline TP53 mutation encodes a protein with an aberrant C-terminal motif in a case of pediatric adrenocortical tumor. Fam Cancer October 22, 2010.

    Liu D, Ou L, Clemenson GD, Chao C, Lutske ME, Zambetti GP, Gage FH, Xu Y. Puma is required for p53-induced depletion of adult stem cells. Nat Cell Biol 12(10):993-U226, 2010.

    Ribeiro RC, Pinto EM, Zambetti GP. Familial predisposition to adrenocortical tumors: clinical and biological features and management strategies. Best Pract Res Clin Endocrinol Metab 24(3):477-90, 2010.

    Steimer DA, Boyd K, Takeuchi O, Fisher JK, Zambetti GP, Opferman JT. Selective roles for anti-apoptotic MCL-1 during granulocyte development and macrophage effector function. Blood 2009 (in press).

    Russell-Swetek A, West AN, Mintern JE, Jenkins J, Rodriguez-Galindo C, Ribeiro R, Zambetti GP. Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma. J Med Genet 45:603-606, 2008.

    Assumpção JG, Seidinger AL, Mastellaro MJ, Ribeiro RC, Zambetti GP, Ganti R, Srivastava K, Shurtleff S, Pei D, Zeferino LC, Dufloth RM, Brandalise SR, Yunes JA. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer 8:357, 2008.

    Garrison SP, Jeffers JR, Yang C, Nilsson JA, Rehg J, Yue W, Yu J, Zhang L, Sample JT, Cleveland JL, Zambetti GP. Selection against PUMA gene expression in Myc-driven B cell lymphomagenesis. Mol Cell Biol 28:5391-5402, 2008 (featured in Nature Reviews of Cancer 8:568-69, 2008).

    Qui W, Carson-Walter EB, Liu H, Epperly M, Greenberger JS, Zambetti GP, Zhang L, Yu J. The BH3-only Protein PUMA regulates intestinal stem cell radiosensitivity. Cell Stem Cell 2:576-583, 2008 (see Preview Cell Stem Cell 2: 517-18, 2008).

    Rosati R, Cerrato F, Doghman M, Pianovski M, Parise GA, Custódio G, Zambetti GP, Riccio A, Ribeiro RC, Figueiredo BC, Lalli E. High frequency of loss of heterozygosity at 11p15 and IGF2 overexpression is not associated with clinical outcome in childhood adrenocortical tumors positive for the R337H TP53 mutation. Cancer Genet Cytogenet 186: 19-24, 2008.

    Zambetti GP. The p53 mutation “Gradient Effect” and its clinical implications. J Cell Phys 213:370-73, 2007.

    Doghman M, Karpova T, Rodrigues G, Arhatte M, De Moura J, Cavalli LR, Virolle V, Barbry P, Zambetti GP, Figueiredo BC, Heckert LL, Lalli E. Increased Steroidogenic Factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol Endo 21:2968-87, 2007.

    Doghman M, Arhatte M, Thibout H, Rodrigues G, De Moura J, Grosso S, Laurent M, Mas JC, Bongain A, Zambetti GP, Figueiredo BC, Auberger P, Martinerie C, Lalli E. NOV/CCN3 is a selective pro-apoptotic factor for adrenocortical cells downregulated in childhood adrenocortical tumors. J Clin Endo Metab 92:3253-60, 2007.

    Ribeiro R, Figueiredo BC, Rodriguez-Galindo C, Mastellaro MJ, West AN, Kriwacki R, Zambetti GP. Germline TP53 R337H mutation is not sufficient to determine Li-Fraumeni or Li-Fraumeni-like syndrome. Can Lett 247:353-55, 2007.

    West AN, Neale GA, Pounds S, Figueredo BC, Rodriguez Galindo C, Pianovski MA, Oliveira Filho AG, Malkin D, Lalli E, Ribeiro R, Zambetti GP. Gene Expression Profiling of Childhood Adrenocortical Tumors. Cancer Res 67:600-608, 2007.

    Wu B, Qiu W, Wang P, Yue W, Yu H, Cheng T, Zambetti GP, Zhang L, Yu J. PUMA is a mediator of p53-independent intestinal apoptosis induced by ischemia reperfusion. Gut 56:645-54, 2007.

    Broniscer A, Baker SJ, West AN, Fraser MM, Kocak M, Dalton J, Zambetti GP, Gajjar A, Gilbertson RJ, Fuller CE Clinical and molecular characteristics of malignant transformation of low-grade glioma in children: the St. Jude Children’s Research Hospital experience. J Clin Oncol 25:682-89, 2007.

    Pianovski MA, Cavalli LR, Figueiredo BC, Santos SC, Doghman M,Ribeiro RC, Michalkiewicz E, Zambetti GP, Haddad BR, Lalli E. SF-1 Overexpression in Childhood Adrenocortical Tumors. Int J Cancer 42:1040-43, 2006.

    Zambetti GP, Horwitz EM, Schipani E. Skeletons in the p53 tumor suppressor closet: Genetic evidence that p53 blocks bone differentiation and development. J Cell Biol 172:795-97, 2006.

    Kim H, Tu HC, Rafiuddin-Shah M, Jeffers JR, Zambetti GP, Hsieh J, Cheng EHY. Hierarchical Regulation of Mitochondrion-Dependent Apoptosis by BCL-2 Subfamilies. Nat Cell Biol 8: 1348-58, 2006 (see News & Views, Nat Cell Biol 8: 1317-19).

    Opferman JT, Zambetti GP. Translational Research? Ribosome integrity and a new p53 tumor suppressor checkpoint. Cell Death Diff 13:898-901, 2006.

    West AN, Ribeiro RC, Jenkins J, Rodriguez-Galindo C, Figueiredo BC, Kriwacki R, Zambetti GP. Identification of a Novel Germline Variant Hotspot Mutant p53-R175L in Pediatric Adrenal Cortical Carcinoma. Can Res 66:5056-62, 2006.

    Toth A, Jeffers JR, Nickson P, Min JY, Morgan JP, Zambetti GP, Erhardt P. Targeted Deletion of Puma Attenuates Cardiomyocyte Death and Improves Cardiac Function during Ischemia/reperfusion. Am J Physiol Heart Circ Physiol 291: 52-60, 2006 (see Editorial Focus).

    Figueiredo BC, Sandrini R, Zambetti GP, Pereira RM, Cheng C, Lacerda L, Pianovski MA, Michalkiewicz E, Jenkins J, Rodriguez-Galindo C, Mastellaro MJ, Vianna S, Sandrini F, Arram SIB, Ribeiro RC. Penetrance of Adrenocortical Tumors Associated with the Germline TP53 R337H Mutation. J Med Genet 43: 91-96, 2006.

    Wu WS, Heinrichs S, Xu D, Garrison SP, Zambetti GP, Adams JM, Look AT. Slug Antagonizes p53-Mediated Apoptosis of Hematopoietic Progenitors by Repressing Puma. Cell 123: 641-53, 2005. (Cover, see Previews).

    Lozano G, Zambetti GP. Gankyrin: An intriguing name for a novel regulator of p53 and RB. Cancer Cell 8:3-4, 2005.

    Myers MC, Wang J, Zambetti GP, Appella DH. Targeting mutant p53 using a new family of small molecules derived from serine. J Am Chem Soc 127:6152-53, 2005.

    Lozano G, Zambetti GP. What have animal models taught us about the p53 pathway? J Path 205:206-20, 2005.

    Figueiredo BC, Cavalli LR, Pianovski MA, Lalli E, Sandrini R, Ribeiro RC, Zambetti GP, DeLacerda L, Rodrigues GA, Haddad BR. Amplification of the steroidogenic factor 1 (SF-1) gene in childhood adrenocortical tumors. J Clin Endo Metab 90:615-19, 2005.

    Rodriguez-Galindo C, de Figueiredo BC, Zambetti GP, Ribeiro RC. Biology, clinical characteristics and management of adrenocortical tumors in children. Pediatric Blood & Cancer 44: 1-9, 2005.

    Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean KH, Han J, Chittenden T, Ihle JN, McKinnon PJ, Cleveland JL, Zambetti GP. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell: 4: 321-328, 2003. (see Previews, Cancer Cell 4: 248-49).

    Lee AS, Galea C, DiGiammarino EL, Jun B, Murti G, Ribeiro RC, Zambetti GP, Schultz CP, Kriwacki RW. Structural polymorphism of the p53 tetramerization domain. J Mol Biol 327: 699-709, 2003.

    Weber JD, Zambetti GP. Renewing the Debate Over the p53 Apoptotic Response. Cell Death Diff 10: 409-12, 2003.

    Zambetti GP, Kastan MB. Overcoming p53 Parking Problems. Cell 112:1-2, 2003.

    DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, Zambetti GP, Kriwacki RW. Evidence for a novel molecular mechanism of tumorigenesis: pH-dependent destabilization of the p53 tetramer. Nat Struct Biol 9:12-16, 2002. (News & Views, Nat Med 8: 21-23, 2002).

    DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, Zambetti G, Kriwacki RW. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 9 (1):12-16, 2002.


    Last update: April 2012